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Novel olanzapine analogues presenting a reduced
H1 receptor affinity and retained 5HT2A/D2
binding affinity ratio
Somayeh Jafari1,2, Marc E Bouillon2, Xu-Feng Huang1,3, Stephen G Pyne2 and Francesca Fernandez-Enright1,3*
Abstract
Background: Olanzapine is an atypical antipsychotic drug with high clinical efficacy, but which can cause severe
weight gain and metabolic disorders in treated patients. Blockade of the histamine 1 (H1) receptors is believed to
play a crucial role in olanzapine induced weight gain, whereas the therapeutic effects of this drug are mainly
attributed to its favourable serotoninergic 2A and dopamine 2 (5HT2A/D2) receptor binding affinity ratios.
Results: We have synthesized novel olanzapine analogues 8a and 8b together with the already known derivative
8c and we have examined their respective in vitro affinities for the 5HT2A, D2, and H1 receptors.
Conclusions: We suggest that thienobenzodiazepines 8b and 8c with lower binding affinity for the H1 receptors,
but similar 5HT2A/D2 receptor binding affinity ratios to those of olanzapine. These compounds may offer a better
pharmacological profile than olanzapine for treating patients with schizophrenia.
Keywords: Olanzapine, Novel antipsychotics, 5HT2A/D2 affinity ratio, H1 receptors
Background
Antipsychotics are widely prescribed for treating severe
psychotic diseases, including schizophrenia, bipolar
mania, and delusional disorders [1-3]. Antipsychotic ther-
apy alleviates symptoms of schizophrenia but can produce
severe side effects. The side effects of antipsychotic medi-
cation vary according to the type of antipsychotic adminis-
tered. Typical antipsychotics such as haloperidol have a
high affinity for dopaminergic subtype 2 (D2) receptors [4-
6]. The blockade of D2 receptors in the mesolimbic dopa-
mine pathways leads to the reduction of the positive
symptoms of schizophrenia such as hallucination and
delusion [4,7]. However, inhibition of D2 receptors in the
mesocortical dopamine pathway can cause emotional and
cognitive problems [8]. In the nigrostriatal pathways, the
reduction of dopamine by typical antipsychotics is
associated with an occurrence of extrapyramidal symp-
toms (EPS), including tardive dyskinesia (TD), dystonia,
akathesia, and Parkinsonism [9]. By blocking D2 receptors
in the mesolimbic dopamine pathway, a reduction of the
positive symptoms is observed. Nevertheless, the lack of
selectivity of typical antipsychotics in blocking D2 recep-
tors in the nigrostriatal and the mesocortical pathway
leads to the expression of various motor disorders as well
as worsening the negative (disturbances in emotion and
behaviour) and cognitive symptoms, respectively [10-12].
Atypical antipsychotics (second generation), on the other
hand, are not only capable of controlling the positive
symptoms of schizophrenia but they are also believed to
improve the therapeutic effects on the negative symptoms
and cognitive dysfunction [9]. Clinical trials have reported
fewer incidents of motor dysfunction with atypical anti-
psychotic treatment compared to typical antipsychotic
medication [13]. Additionally, atypical antipsychotic
agents have both serotonin 2A (5HT2A) and D2 receptors
antagonist properties while typical antipsychotics mainly
bind to the D2 receptors [14]. A higher affinity of atypical
antipsychotics for the 5HT2A receptors compared to D2
receptors has been hypothesized for their enhanced effi-
cacy and reduced incidences of EPS [4].
Tetracyclic compounds such as clozapine (1) and olan-
zapine (2) are one of the most prominent representatives
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for atypical antipsychotics (Figure 1). These antipsycho-
tics showed a regional preference for the mesolimbic
dopamine receptors and also an optimum pKi 5HT2A/D2
binding affinity ratio [15]. Over the last decade, olanza-
pine with its thienobenzodiazepine core structure has
been the first choice agent in the therapy of schizophre-
nia due to its high clinical efficacy [16]. However, treat-
ment with olanzapine and the majority of the atypical
antipsychotic agents is accompanied by excessive weight
gain and severe metabolic side effects such as type II
diabetes mellitus, hyperglycemia, dyslipidemia, and insu-
lin resistance [1,3,17-20]. These antipsychotic drugs are
liable for a complex of pathological changes in which
not a single factor can be accountable for the induced
metabolic side effects. Changes in hormonal peptide
levels correlated with food intake (such as insulin and
leptin) have been suggested to play a part in weight gain
induced by atypical antipsychotic drug treatment [21].
Clozapine and olanzapine medications [22,23] in par-
ticular significantly influence the regulation of plasmatic
insulin and leptin, although the mechanism of action
remains elusive. A large number of studies have also
reported a relevant role for the affinities of atypical anti-
psychotics for the 5HT2A, 5HT6, 5HT7, α1A, and particu-
larly H1 and 5HT2C receptors in their obesogenic effects
[24-27].
There is much compelling evidence of the involvement
of 5HT2C receptors in satiety, food intake and body
weight reviewed in [28]. It is reported that 5HT2C antag-
onism or inverse agonism may contribute to olanzapine-
induced weight gain [29]. A study on mice revealed that
animals with selectively expressed 5HT2C receptors only
in POMC neurons are obese and hyperphagic, suggest-
ing that POMC neurons mainly mediate the effects of
5HT2C receptors on energy balance [30]. Moreover, pre-
vious findings presented evidence that 5HT2C receptor
and leptin gene polymorphisms, and smoking are im-
perative risk factors influencing the development of
metabolic side effects in patient receiving antipsychotic
drug treatments [31,32]. There are other receptors
mechanism recognized with synergistic effect on weight
gain and metabolic dysfunctions induced by anti-
psychotic drugs. D2 receptor antagonism, for instance,
can influence feeding behaviour [33], with an increase in
5HT2C-mediated effects on food intake. In addition, a
disruption of rewarding mechanisms by D2 receptor
blockade in the dopamine reward system might results
in a disinhibition of food intake; however, these effects
are of less concern for the atypical antipsychotic drugs
as their 5HT2A antagonism proprieties attenuate the dis-
ruption of reward mechanisms by D2 antagonism
[27,34].
The blockade of the H1 receptors has been repeatedly
described as the most likely mechanism for atypical anti-
psychotic drug-induced weight gain [35-38]. The inhib-
ition of the H1 receptors is directly involved in the
activation of hypothalamic AMPK signaling, which sti-
mulates food intake and positive energy balance and
reverses the anorexigenic effect of leptin [36]. A strong
link between the H1 receptor affinity of antipsychotic
agents and their weight gain propensity has been
reported [39]. Clozapine and olanzapine which have
higher affinity for the H1 receptors (Ki = 1.2 nM and
Ki = 2.0 nM, respectively) showed a greater propensity to
induce weight gain [40,41]. However, tetracyclic anti-
psychotic drugs with lower H1 antagonist affinity, such
as loxapine (3) and amoxapine (4) (Figure 1) caused nei-
ther weight gain nor weight loss in patients treated with
these medications [42,43]. Thus, the development of a
novel antipsychotic agent with similar 5HT2A/D2 recep-
tor binding affinity ratio to that of olanzapine and with a
lower affinity to the H1 receptors may significantly ad-
vance schizophrenia therapy. For the last several years,
researches have been focused on developing novel anti-
psychotics with fewer metabolic side effects [44]. Never-
theless, the crucial needs for developing an ideal
antipsychotic agent for schizophrenia still continue. In
this study, we synthesized two novel derivatives of olan-
zapine (8a and 8b) and the previously reported analogue
8c [45], presenting two alterations to the structure of
olanzapine such as the substitution of an ethyl group at
the C-2 position of the thiophene ring (8b and 8c) and
the replacement of the N-methylpiperazine with an N-
methylhomopiperazine ring (8a and 8b) (Scheme 1). We
then evaluated the affinities of these compounds for
Figure 1 Structures of tetracyclic atypical antipsychotics.
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serotoninergic, dopaminergic, and histaminergic recep-
tors in the prefrontal cortex, striatum, and hypothalamus
respectively, which is relevant to their therapeutic and
metabolic side effects.
Results
The syntheses of thienobenzodiazepines 8b and 8c were
based on the procedure previously reported for the prep-
aration of olanzapine by Shastri et al. [46] (Scheme 1)
with some modifications. The condensation of 2-amino-
5-ethylthiophene-3-carbonitrile (5b) with 1-fluoro-2-
nitrobenzene followed by the intramolecular reductive
cyclization of the thiophene-3-carbonitrile 6b in the
presence of stannous chloride led to amidine 7b in 80%
over 2 steps. This primary amidine was the key precur-
sor for our two target compounds 8b and 8c. Treatment
of amidine 7b with N-methylpiperazine in conjugation
with N-methylpiperazine hydrochloride salt in DMSO at
110 – 120°C afforded 8c in 56% yield as bright yellow
crystals. Interestingly, when amidine 7b was reacted with
N-methylhomopiperazine and N-methylhomopiperazine
hydrochloride under the same conditions, 8b was
obtained in low yield (<20%) and purity due to the for-
mation of many by-products, including the dimer of 8b.
Optimization of this step was therefore necessary for a
more efficient production of compound 8b. After many
explorations, we found that the reaction time to be the
crucial factor in this process. Thus, to accelerate the re-
action we applied microwave irradiation instead of con-
ventional oil bath heating of the reaction mixture. This
modification led to a reduction of the reaction time from
20 h to 3 h. Due to the shorter reaction time, the forma-
tion of the undesirable by-products was avoided and the
yield of compound 8b consequently increased. Further-
more, we found that the addition of N-methylhomopi-
perazine hydrochloride and a solvent was not necessary
for the successful outcome of this reaction. When finally
performed under solvent free conditions and microwave
heating at 120°C for 3 h, then compound 8b was
obtained in an improved yield of 55%. The synthesis of
compound 8a required even milder reaction conditions
to suppress side reactions. Thus, the microwave reaction
of the commercially available amidine 7a with N-methyl-
homopiperazine at 80°C for 4 h led to the formation of
thienobenzodiazepine 8a in 65% yield.
Next, we examined the receptor binding affinities of
compounds 8a, 8b and 8c for D2, 5HT2A, and H1 recep-
tors in Sprague Dawley rats. The assays used were stand-
ard in vitro radioligand binding assays. Radioligand
binding assays were run under the conditions described
previously with some modifications [47,48]. The affin-
ities of compound 8c for the D2 and 5HT2A receptors
were similar to the values found for olanzapine
(P= 0.561 and P= 0.959, respectively) (Table 1). How-
ever, compound 8b showed less binding affinities than
olanzapine for D2 and 5HT2A receptors (P= 0.002 and
P= 0.030, respectively). The pKi ratios 5HT2A/D2 of 8c
and 8b were similar to the value of olanzapine (P= 0.137
and P= 0.457, respectively). This value ratio is consistent
with the previously reported one for olanzapine in the
literature [47,49]. Compounds 8a displayed a significant
reduction in binding to the D2 and 5HT2A receptors
(P= 0.001 and P= 0.001, respectively) receptors. The
binding affinity of 8c, 8b, and 8a for H1 receptors was
Table 1 Binding affinities of olanzapine, compounds 8a,
8b, and 8c for 5HT2A, D2, and H1 receptors





olanzapine 67.72 ± 9.21 4.22 ± 0.77 0.13 ± 0.02 1.17
8c 54.51 ± 12.12 3.70 ± 0.74 1.95 ± 0.33* 1.16
8b 791.08 ± 83.19** 81.20 ± 2.43* 13.63 ± 2.68*** 1.16
8a 3939.90 ± 437.35*** 787.00 ± 29.81*** 33.50 ± 7.39*** 1.16
a Values are the mean ± SD of four to six experiments and represent the
concentration giving half maximal inhibition of [3H]-Spiperone (D2), [
3H]-
Ketanserine (5HT2A), and [
3H]-Pyrilamine (H1) binding to rat tissue




















5a (R = CH3)
5b (R = C2H5)
6a (R = CH3)
6b (R = C2H5)
7a (R = CH3)
7b (R = C2H5)
8a (R = CH3,
n = 1)
8b (R = C2H5,
n = 1)
8c (R = C2H5,
n = 0)
Scheme 1 Synthesis of compounds 8a, 8b, and 8c. Reagents and
conditions: (i) 1-fluoro-2-nitrobenzene, NaH, THF, rt, 20 h, 60%; (ii) SnCl2,
EtOH, 80°C, 1 h, 80%; (iiia) N-methylhomopiperazine (5 equiv), no
solvent, microwave heating, 80°C, 4 h,65%; (iiib) N-
methylhomopiperazine (5 equiv), no solvent, microwave heating, 120°
C, 3 h, 55%; (iiic) N-methylpiperazine (10 equiv), N-methylpiperazine
hydrochloride (10 equiv), DMSO, 110–120°C, 20 h, 56%.
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significantly reduced compared to olanzapine (P= 0.033,
P= 0.001, and P= 0.001, respectively).
Discussion
Compound 8c with an ethyl substituent at position 2 of
the thiophene ring conferred a lower affinity for the H1
receptors but similar affinities for the D2 and 5HT2A
receptors when compared to olanzapine. This may suggest
the potential contribution of a C-2 ethyl substituent to the
potency of binding to the histaminergic receptors but not
to the serotoninergic and dopaminergic receptors. On the
other hand, the replacement of the N-methylpiperazine
ring of compound 8c with an N-methylhomopiperazine
ring (8b) led to a reduction of the affinities for dopamine
and serotonin receptors. This decrease of receptor affin-
ities is probably caused by an unfavorable steric inter-
action of the N-methylhomopiperazine ring with amino
acid residues in the binding pocket of the D2 and 5HT2A
receptors. Lower affinity of compound 8b for the H1
receptors compared to olanzapine could be due to both
the ethyl group and the N-methylhomopiperazine ring
substitution. Although compound 8b has lower affinity
than olanzapine or compound 8c for the D2 and 5HT2A
receptors, it possessed a favorable pKi ratio 5HT2A/D2
similar to the measured value of olanzapine (ratio value=
1.17). Moreover, the obtained binding affinity of com-
pound 8b (Table 1) for the D2 receptor is still comparable
to that value of remoxipride (Ki: 800 nM) and quetiapine
(Ki: 680 nM) [50], atypical antipsychotics with high thera-
peutic efficacy in the clinic. Therefore, it is assumed that
the therapeutic effectiveness of compound 8b may be
delivered at higher doses than that of olanzapine adminis-
tered. However, without appropriate comparison of
DMPK (Drug Metabolism/Pharmacokinetics) properties
between these mentioned antipsychotics (quetiapine,
remoxipride, and olanzapine) and compound 8b, the
above notion could be an over-prediction. As a part of
drug development process, it is crucial to investigate the
preclinical toxicity and pharmacodynamics properties of
the candidate drugs before risking and enhancing the pos-
sibility of further costly development.
Similarly, the presence of the N-methylhomopipera-
zine ring in thienobenzodiazepine 8a caused a significant
reduction in binding to the D2 and 5HT2A as well as the
H1 receptors. The low binding affinity of compound 8a
for the D2 and 5HT2A receptors may be due to a lower
bioactive conformational state for the tricyclic thieno-
benzodiazepine skeleton. Steric effect of the N-methyl-
homopiperazine ring may also affect the rotation of this
ring around the tricyclic thienobenzodiazepine, resulting
in a lower interaction with the D2 receptors in com-
pounds 8a and 8b. However, the extension at the C-2
position of the thiophene ring with an ethyl group in
compound 8b seems to improve the affinities for the D2
and 5HT2A receptors when compared to those values of
compound 8a.
Taking these results into account, it appears that the
N-methylhomopiperazine ring is not a favorable group
for the interaction of the molecule with serotonin and
dopamine receptors. The distances between the centroid
of the fused thiophene and phenyl rings and the basic
distal nitrogen as well as the conformational state of the
tricyclic thienobenzodiazepine are essential parameters
for the affinity of the molecule for the D2 and 5HT2A
receptors [49]. Presumably, alteration in these distances
in OlzHomo 8b and MeHomo 8a structures is involved
in the lower affinity of these compounds for the D2 and
5HT2A receptors compared to olanzapine.
We suggest that both compounds 8b and 8c may
present therapeutic effectiveness for treating schizophre-
nia. In addition, these compounds present a lower affin-
ity for H1 receptors, which may have reduced effects on
weight gain and metabolic disorders than those reported
with olanzapine. Nonetheless, given the potential safety-
concerns of these new compounds and the previously
reported inconsistencies of antipsychotic-induced weight
gain shown in animal models and in clinic, the present
results should be taken with a degree of caution. Clinical
studies showed that weight gain is liable to occur with
any antipsychotic drug treatment. Moreover, the extent
to which these drugs cause weight gain and metabolic
dysregulation vary according to the type of antipsycho-
tics prescribed and inter-individual differences in re-
sponse to treatment and susceptibility to development of
metabolic syndromes; therefore, we suggested that only
further comprehensive animal studies and clinical trials
will reveal the predictive validity of therapeutic efficacy
and metabolic side effects of these two compounds.
Conclusions
In summary, in this study we have synthesized olanzapine
derivatives 8a, 8b, and 8c and we have evaluated the affin-
ities of these compounds for the brain 5HT2A, D2, and H1
receptors. Compound 8c represents a potential anti-
psychotic agent characterized by a highly favorable bind-
ing profile at 5HT2A and D2 receptors, similar to
olanzapine, as well as lower affinity for H1 receptors.
These results may suggest the potential role of a C-2 ethyl
group in reducing binding affinity to the H1 receptors.
Compounds 8a and 8b with a bulky seven-membered ring
presented lower binding affinities to all the tested recep-
tors. Taking into account that the D2 affinity of thienoben-
zodiazepine 8b is still comparable with that value of the
high potent antipsychotics, we suggest that both com-
pounds 8b and 8c may present therapeutic effectiveness
for treating schizophrenia. In addition, these compounds
present a lower affinity for H1 receptors, which may have
reduced effects on weight gain and metabolic disorders
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than those reported with olanzapine; however, given the
fact that at the state-of-the-art the emergence of weight
gain is possible following any antipsychotics treatment, we
suggested that the present results be taken with caution.
Only further animal studies and clinical trials will shed
light on the therapeutic effectiveness and metabolic side
effects of these two compounds.
Methods
Synthetic procedures
A solution of amidine hydrochloride 7b (1.62 mmol,
455 mg), methyl piperazine (10 equiv, 16.2 mmol,
3300 mg) and methyl piperazine hydrochloride (16.2 mmol,
3400 mg) in DMSO (15 mL) was heated to110°C for 20 h
(Figure 2). After cooling to room temperature the reaction
mixture was diluted with dichloromethane and washed
twice with 1 M aqueous HCl solution. The dark brown
colored hydrochloride was separated and basified to pH
7.5 – 8.5, using 1 M aqueous NaOH solution. The attained
solution was extracted with dichloromethane and washed
twice with brine, then dried over MgSO4 and concentrated
under reduced pressure to provide a brown oil. The crude
product was purified by column chromatography and then
crystallized from acetonitrile to give the desired product
(296 mg) as bright yellow crystals in 56% yield. 1H NMR
(500 MHz, CDCl3) δ [ppm]: 1.21 (t, 3H, J=7.5 Hz, H3C-
200), 1.97 (quin, 2H, J=5.7 Hz, H2C-6′), 2.39 (s, 3H, CH3 at
N-4′), 2.64 (m, 4H, H2C-100 & H2C-5′), 2.71 (t, 2 H,
J=4.5 Hz, H2C-3′), 3.68 (t, 2H, J=5.7 Hz, H2C-7′), 3.74 (t,
2H, J=4.5 Hz, H2C-2′), 5.02 (s, 1 H, HN-10), 6.35 (s, 1H,
HC-3), 6.60 (dd, 1H, J1 = 1.3 Hz, J2 = 7.8 Hz, HC-9), 6.82
(dt, 1H, J1 = 1.8 Hz, J2 = 7.8 Hz, HC-8), 6.94 (dt, 1H,
J1 = 1.5 Hz, J2 = 7.5 Hz, HC-7), 7.00 (dd, 1H, J1 = 1.8 Hz,
J2 = 7.8 Hz, HC-6).
13C NMR (125 MHz, CDCl3) δ [ppm]:
15.6 (CH3, C-200), 23.6 (CH2, C-100), 28.1 (CH2, C-6′), 46.8
(CH3, N-4′), 48.4 (CH2, C-7′), 48.5 (CH2, C-2′), 58.0 (CH2,
C-5′), 58.6 (CH2, C-3′), 118.9 (CH, C-9), 120.0 (Cq, C-3a),
121.2 (CH, C-3), 122.8 (CH, C-8), 124.6 (CH, C-7), 127.9
(CH, C-6) 136.8 (Cq, C-2), 141.7 (Cq, C-5a), 142.3 (Cq, C-9a),
150.9 (Cq, C-10a), 157.1 (Cq, C-4). IR (neat) νmax [cm
−1]:
2967(w), 2930(w), 2916(w), 2850(w), 1584(vs), 1558(s),
1514(w), 1464(s), 1410(s), 1362(m), 1317(w), 1287(w),
1240(m), 1212(m) 1168(m), 1128(m), 1086(w), 1038(m),
1017(w), 963(w), 912(m), 864(w), 856(w), 837(w), 822(w),
810(w), 804(w), 755(m), 737(m), 722(m), 711(m). HRMS (ESI)
calcd for C18H23N4S [M+H]
+ 327.1643, found 327.1642.
A mixture of amidine hydrochloride 7b (0.34 mmol,
96 mg) and N-methylhomopiperazine (5 equiv, 1.71 mmol,
195 mg) was stirred at 120°C for 3 h under microwave
heating in a sealed reactor tube (Figure 3). After cooling to
room temperature the reaction mixture was diluted with
dichloromethane (3 ml) and washed twice with saturated
sodium bicarbonate solution. The organic phase was
washed with brine, then dried over MgSO4 and concen-
trated under reduced pressure to provide a brown oil. The
crude product was purified by column chromatography to
give the desired product as a brown powder (64 mg) in
55% yield. 1H NMR (500 MHz, CDCl3) δ [ppm]: 1.21 (t,
3H, J=7.5 Hz, H3C-200), 1.97 (quin, 2H, J=5.7 Hz, H2C-
6′), 2.39 (s, 3H, CH3 at N-4′), 2.64 (m, 4H, H2C-100 &
H2C-5′), 2.71 (t, 2H, J=4.5 Hz, H2C-3′), 3.68 (t, 2H,
Figure 2 Procedure for the synthesis of compound (2-ethyl-4-
(4′-methylpiperazin-1′-yl)-10Hbenzo[b]thieno[2,3-e][1,4]
diazepine (8c).
Figure 3 Procedure for the synthesis of compound (2-ethyl-4-
(4′-methyl-1′,4′-diazepan-1′-yl)-10H-benzo[b]thieno[2,3-e] [1,4]
diazepine (8b).
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J=5.7 Hz, H2C-7′), 3.74 (t, 2H, J=4.5 Hz, H2C-2′), 5.02
(s, 1H, HN-10), 6.35 (s, 1H, HC-3), 6.60 (dd, 1H,
J1 = 1.3 Hz, J2 = 7.8 Hz, HC-9), 6.82 (dt, 1H, J1 = 1.8 Hz,
J2 = 7.8 Hz, HC-8), 6.94 (dt, 1H, J1 = 1.5 Hz, J2 = 7.5 Hz,
HC-7), 7.00 (dd, 1H, J1 = 1.8 Hz, J2 = 7.8 Hz, HC-6).
13C
NMR (125 MHz, CDCl3) δ [ppm]: 15.6 (CH3, C-200), 23.6
(CH2, C-100, 8.1 (CH2, C-6′), 46.8 (CH3, N-4′), 48.4 (CH2,
C-7′), 48.5 (CH2, C-2′), 58.0 (CH2, C-5′), 58.6 (CH2, C-3′),
118.9 (CH, C-9), 120.0 (Cq, C-3a), 121.2 (CH, C-3), 122.8
(CH, C-8), 124.6 (CH, C-7), 127.9 (CH, C-6), 136.8 (Cq, C-
2), 141.7 (Cq, C-5a), 142.3 (Cq, C-9a), 150.9 (Cq, C-10a),
157.1 (Cq, C-4). IR (neat) νmax [cm
−1]: 2940(w), 2850(w),
2803(w), 1583(vs), 1557(s), 1513(w), 1464(s), 1410(s), 1357
(m), 1317(w), 1288(m), 1247(m), 1196(m), 1017(w), 959(w),
910(m), 860(w), 848(w), 834(w), 830(w), 814(w), 753(vs),
740(s), 730(m), 717(w), 711(w), 702(w). HRMS (ESI) calcd
for C19H25N4S [M+H]
+ 341.1800, found 341.1802.
A mixture of amidine hydrochloride 7a (1 mmol,
260 mg) and N-methylhomopiperazine (5 equiv, 5 mmol,
and 534 mg) was stirred at 80°C for 4 h under micro-
wave heating in a sealed reactor tube (Figure 4). After
cooling to room temperature the reaction mixture was
diluted with dichloromethane (5 ml) and washed twice
with saturated sodium bicarbonate solution. The organic
phase was washed with brine, then dried over MgSO4
and concentrated under reduced pressure to provide a
brown oil. The crude product was purified by column
chromatography to afford the desired product as a dark
red powder (212 mg) in 65% yield. 1H-NMR (500 MHz,
CDCl3) δ [ppm]: 1.97 (quin, 2H, J= 5.5 Hz, H2C-6′),
2.30 (s, 3H, H3C-100), 2.39 (s, 3H, CH3 at N-4′), 2.65 (t,
2H, J= 5.5 Hz, H2C-5′), 2.71 (t, 2H, J= 4.5 Hz, H2C-3′),
3.68 (t, 2H, J= 5.5 Hz, H2C-7′), 3.74 (s, 2H, H2C-2′)
4.96 (s, 1H, HN-10), 6.33 (s, 1H, HC-3), 6.61 (d, 1H,
J= 7.5 Hz, HC-9), 6.82 (t, 1H, J= 7.5 Hz, HC-8), 6.95 (t,
1H, J= 7.5 Hz, HC-7), 7.00 (d, 1H, J= 7.5 Hz, HC-6).
13C-NMR (125 MHz, CDCl3) δ [ppm]: 15.8 (CH3, C-100),
28.3 (CH2, C-6′), 47.0 (CH3, N-4′), 48.6 (CH2, C-7′),
48.7 (CH2, C-2′), 58.2 (CH2, C-5′), 58.9 (CH2, C-3′),
119.0 (CH, C-9), 120.5 (Cq, C-3a), 123.0 (CH, C-8),
123.2 (CH, C-3), 124.9 (CH, C-7), 128.1 (CH, C-6), 129.5
(Cq, C-2), 141.9 (Cq, C-5a), 142.4 (Cq, C-9a), 151.2 (Cq,
C-10a), 157.1 (Cq,C-4). IR (neat) νmax [cm
-1]: 2940(w),
2850(w), 2803(w), 1583(vs), 1557(s), 1513(w), 1464(s),
1410(s), 1357(m), 1317(w), 1288(m), 1247(m), 1196(m),
1169(m), 1123(m), 1085(w), 1038(w), 1017(w), 959(w),
910(m), 860(w), 848(w), 834(w), 830(w), 814(w), 753(vs),
740(s), 730(m), 717(w), 711(w), 702(w). HRMS (ESI)
calcd for C18H23N4S [M+H
+] 327.1643, found 327.1642.
Membrane binding assay
The prefrontal cortex, striatum and hypothalamus were
homogenized in about 6 volumes of ice-cold buffer Tris.HCl,
50 mM, pH 7.7 (for D2 and 5HT2A receptors) or Na
+/K+
phosphate 50 mM, pH 7.5 (for H1 receptors), and the re-
sultant homogenate was then centrifuged (27000 g for
15 min at 4°C). Each pellet was resuspended in the same
volume of fresh buffer and centrifuged again under the
same conditions as above. The final tissue pellets were
resuspended just before the binding assay in the incuba-
tion buffer (50 mM Tris.HCl, 5 mM MgSO4, 0.5 mM
EDTA and 0.02% ascorbic acid, pH 7.7 for D2 receptors;
50 mM Tris.HCl, pH 7.7 for 5HT2A receptors and Na
+/K+
phosphate 50 mM, pH 7.5 for H1 receptors). [
3H]-Spiper-
one (specific activity, 15 Ci/mmol, 1 mCi/ml; Perkin
Elmer, Australia) binding to D2 receptor was assayed for
40 min at 37°C in the presence of 2 nM radioligand solu-
tion, 1.2 mg/mL protein suspension with/without serial
concentration of displacers (olanzapine, 8a, 8b, and 8c)
The binding affinity at 5HT2A receptors was measured in
the presence of 10 nM [3H]-Ketanserine (specific activity,
67 Ci/mmol, 1 mCi/ml; Perkin Elmer, Australia), protein
suspension (0.25 mg/mL), with/without serial concentra-
tion of displacers. The reaction was carried out for 15 min
at 37°C. [3H]-Pyrilamine (specific activity, 37 Ci/mmol,
1 mCi/ml; Perkin Elmer, Australia) binding to H1 receptor
was assayed for 30 min at 25°C in the presence of radioli-
gand solution (2 nM) with/without serial concentration of
displacers. Incubation reactions were stopped by the
addition of ice-cold buffer (Tris.HCl, 50 mM, pH 7.7 for D2
and 5HT2A receptors and Na
+/K+ phosphate 50 mM for H1
receptors) followed by rapid filtration on filter (GF/B What-
man). The filters were then washed twice with the buffer.
The radioactivity on the filters was measured by beta liquid
scintillation analyser (Perkin Elmer, Tri-Crab 2800 TR) with
Figure 4 Procedure for the synthesis of compound (2-methyl-4-
(4′-methyl-1′,4′-diazepan-1′-yl)-10H-benzo[b]thieno[2,3-e] [1,4]
diazepine (8a).
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a counting efficiency of 47%. IC50 values for olanzapine
(Bosche Scientific) and compounds 8a, 8b, and 8c were
determined from competition curves and converted to Ki
values using the Cheng-Prusoff equation [51]. Protein con-
centrations were determined by the Bradford method [52].
Statistical analysis
Data are presented as the means ± S.D. or averages. The
significance of differences between two groups was eval-
uated using one-way ANOVA. The difference is consid-
ered as significant when the P value is less than 0.05.
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